Audited financial results are evidence, that the Group of JSC “Grindeks” worked successfully during last year – net profit, related to the shareholders of the holding company, in 2007 amounted to 7.1 million lats, which is by 8 % more than in 2006. In 2007 turnover of the Group amounted to 51.5 million lats, which is by 9.3 million lats or 22% more than during the same period in 2006.

Chairman of the Board of JSC “Grindeks” Janis Romanovskis denoted, that the positive financial results, shown during 2007, confirm the development of the Company in accordance with its chosen strategic aims. „Significant investments are our utmost guarantor in the development - almost 9 million lats in 2007. The unique in the Baltic States Analytical and Scale-up Laboratory Completed is certified at international level, the production of disposable ready-made medications is continued, and the building of modern waste water purification equipment is started. The growth of JSC “Grindeks” medications sales` volume in existent markets is uninterruptedly continuous; moreover, we started the registration of various medications in the perspective markets, such as China and Turkey”.

JSC “Grindeks” is the leading pharmaceutical company in the Baltic States. Its main fields of action are: research, development and manufacturing of brand products, generics and active pharmaceutical ingredients. JSC “Grindeks” specializes in the heart and cardiovascular, CNS and anti-cancer medication therapeutic groups. JSC “Grindeks” Group consists of four subsidiary companies in Latvia, Estonia and Russia and of representatives and representative offices in fourteen countries. JSC “Grindeks”products are exported to more than 40 countries and its export comprises more than 92% of the total turnover. The main markets are: the Baltic States, Russia and CIS countries, Japan, the USA. JSC “Grindeks”shares are listed in the Official List of Riga Stock Exchange.